Comparing ReShape Lifesciences (OTCMKTS:RSLSD) and Perspective Therapeutics (NASDAQ:CATX)

Perspective Therapeutics (NASDAQ:CATX) and ReShape Lifesciences (OTCMKTS:RSLSD) are both small-cap manufacturing companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, institutional ownership and analyst recommendations.

Profitability

This table compares Perspective Therapeutics and ReShape Lifesciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Perspective Therapeutics	N/A	N/A	N/A
ReShape Lifesciences	-668.58%	-163.22%	-52.10%

Risk and Volatility

Perspective Therapeutics has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500. Comparatively, ReShape Lifesciences has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Perspective Therapeutics and ReShape Lifesciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perspective Therapeutics	0	0	3	0	3.00
ReShape Lifesciences	0	0	0	0	0.00

Perspective Therapeutics presently has a consensus price target of $10.00, indicating a potential upside of 316.67%. Given Perspective Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Perspective Therapeutics is more favorable than ReShape Lifesciences.

Earnings and Valuation

This table compares Perspective Therapeutics and ReShape Lifesciences”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perspective Therapeutics	N/A	N/A	N/A	($0.90)	-2.67
ReShape Lifesciences	$610,000.00	0.00	-$81.15 million	N/A	N/A

Perspective Therapeutics has higher earnings, but lower revenue than ReShape Lifesciences.

Institutional and Insider Ownership

54.7% of Perspective Therapeutics shares are owned by institutional investors. 3.7% of Perspective Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Perspective Therapeutics beats ReShape Lifesciences on 8 of the 10 factors compared between the two stocks.

About Perspective Therapeutics

Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. Isoray, Inc. was founded in 1998 and is based in Richland, Washington.

About ReShape Lifesciences

ReShape Lifesciences Inc., a medical device company, focuses on the design, development, and commercialization of technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. The company's product portfolio includes ReShape vBloc, a therapy that enables patients to feel full and eat less by intermittently blocking hunger signals on the vagus nerve; ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without permanently changing patient anatomy; and Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in October 2017. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in San Clemente, California.